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Abstract Viozan TM (sibenadet HCI, AR-C68397AA) is a novel dual D 2 dopamine receptor, ~2-adrenoceptor agonist, 
developed specifically to treat the key symptoms of chronic obstructive pulmonary disease (COPD), breathlessness, cough 
and sputum.The dual sensory nerve modulation and bronchodilator effects of sibenadet have been demonstrated in initial 
dose-ranging studies of patients with COPD and large-scale clinical evaluation has now been completed. Sibenadet efficacy 
was determined by assessing symptomatic hanges, as defined by the novel assessment ool, the Breathlessness, Cough 
and Sputum Scale (BCSS©).The findings of two placebo-controlled studies are reported. 
These multicentre, double-blind, placebo-controlled studies recruited over 2000 patients with stable COPD, randomized to 
receive sibenadet (500 llg) or placebo, pressurized metered-dose inhaler (pMDI) (three times daily) for a period of 12 or 
26 weeks. Diary cards were completed daily by patients throughout he study to record BCSS scores, peak expiratory flow 
(PEF), study drug and rescue bronchodilator usage, changes in concomitant medication and adverse events.The primary 
endpoints were defined as change from baseline to the final 4weeks of the treatment period in mean BCSS total score, 
and forced expiratory volume in one second (FEVj) measured I hour after administration of the final dose of study drug 
and expressed as a percentage of the predicted FEV I. In addition, clinic assessments were made to determine changes in 
pulmonary function, health-related quality of life, perception of treatment efficacy and adverse events. 
Despite initial improvements in mean daily BCSS total scores in patients receiving sibenadet, he difference in the change 
from baseline to the final 4weeks of the treatment period between the two treatment groups was neither statistically 
significant, nor considered to be of clinical importance. Although marked bronchodilator activity was seen early on with 
sibenadet reatment, the duration of effect diminished as the studies progressed. Sibenadet use was not associated with 
any safety concerns. 
These studies, utilizing the novel BCSS, have clearly illustrated that, despite initial symptomatic improvement with sibenadet 
therapy, this clinical benefit was not sustained over the course of the study. 
© 2003 Elsevier Science Ltd 
INTRODUCTION 
Despite the differing aetiologies of asthma and chronic 
obstructive pulmonary disease (COPD), therapeutic 
strategies for COPD rely largely on drugs developed for 
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patients with asthma. Bronchodilators therefore repre- 
sent the cornerstone of therapy for COPD, despite the 
fact that this patient population, by definition, has limited 
airway reversibility (I-3). Recognition of the increasing 
prevalence of COPD and its associated healthcare 
burden has led to the investigation of a number of 
potential new therapies in recent years.As sensory nerve 
pathways in the lung have been associated with COPD 
symptoms, modulation of reflex responses to stimuli has 
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been one of the approaches investigated (4,5). Since 
agonism at dopamine receptors is generally associated 
with an inhibitory effect in the peripheral nervous 
system (6), the dopamine pathway in the lung has been 
identified as a potential target for drug intervention in 
controlling COPD symptoms (7). Expression of 
D2dopamine receptors on the sensory neurons of 
thoracic dorsal root ganglia has recently been 
demonstrated at the level of both mRNA and protein 
(8). Since these neurons activate pro-inflammatory reflex 
responses and neurogenic inflammation, D2dopamine 
receptor agonists may exert anti-inflammatory effects in 
a number of organs, including the airways. 
Viozan TM (sibenadet HCI, AR-C68397AA) is the first 
in a novel class of dual D 2 dopamine receptor, ~2-adreno- 
ceptor agonists. This drug combines the activity of a 
conventional ~2-adrenoceptor agonist with the novel 
sensory modulatory effects of a dopaminergic 
mechanism.While the role of ~2-adrenoceptor agonists 
in the treatment of COPD is well established, dopamine 
agonism is an entirely unique approach.This activity has 
been investigated in animal models and the D2-receptor 
agonist activity of sibenadet has shown the ability to 
inhibit sensory nerve activity, inhibiting reflex cough, 
mucus production and tachypnoea (9). 
Symptom assessment has become a common outcome 
measure in intervention studies in COPD, despite the 
absence of a widely used symptom measurement ool. 
During the initial clinical investigation of sibenader~ a 
simple outcome measure for the assessment of the key 
symptoms of COPD was developed, the Breathlessness, 
Cough and Sputum Scale (BCSS ©) (10,1 I).This novel, 
patient-reported outcome measure evaluates the 
severity of the three key symptoms of COPD and is 
described in detail by Leidy et al. (10,1 I). Independent 
assessment of the BCSS has shown it to be internally 
consistent and reproducible, and provides supportive 
evidence of its construct, concurrent~ and divergent 
validity (I 0, I I).These analyses support use of the BCSS 
to measure the benefit of therapeutic interventions in 
COPD. Utilization of this novel tool in early clinical 
studies enabled demonstration of symptomatic 
improvement in patients receiving sibenadet and 
indicated superiority over bronchodilator therapy (12). 
The sibenadet efficacy observed in the initial clinical 
evaluations (12) provided the impetus to evaluate 
further the efficacy and safety of sibenadet in longer- 
term studies.Therefore, a large-scale clinical programme 
was initiated and has now been completed.The findings 
of two placebo-controlled studies of sibenader~ of 3- and 
6-month duration, are reported. The primary objective 
of these investigations was to assess the clinical activity 
of sibenadet by recording change in key symptoms as 
determined by the BCSS total score, together with 




Male and female patients, aged 40-80 years, with stable 
COPD, symptoms for > 2 years, a smoking history of at 
least 15 pack-years, pre- and post-bronchodilator 
FEVJFVC (forced vital capacity) < 65%, and pre- and 
post-bronchodilator FEV I 20-70% of the predicted 
normal, were included in the study. Concomitant 
corticosteroids, mucolytics, methylxanthines, anti- 
tussives and decongestants were allowed, provided that 
they were not initiated during the study, and that the 
doses remained constant during the 6 weeks before the 
study, and over the baseline period. 
Patients not eligible for the study included those with 
other significant diseases, evidence of an exacerbation in 
the previous 6weeks, requirement for domiciliary 
oxygen, previous participation in a clinical study of 
sibenader~ participation in any clinical study in the 
previous 3 months, laboratory abnormalities or use of 
disallowed medication (long-acting bronchodilators, oral 
~-agonists, anticholinergics, leukotriene antagonists, 
dopamine agonists or antagonists, ~-adrenoceptor 
blockers, bupropion hydrochloride). 
Study design 
These multi-centre, double-blind, randomized, placebo- 
controlled studies were of 12- and 26-week duration 
(Studies I and 2 respectively). Eligible patients were 
enrolled into a 2-week baseline assessment period. 
Disallowed medications were withdrawn and patients 
were supplied with salbutamol (1001~g) (Ventolin TM, 
Glaxo SmithKline) as pressurized metered-dose 
inhalers (pMDIs) for use as rescue medication. Patients 
were required throughout he study to complete daily 
diary cards recording symptoms, morning and evening 
peak expiratory flow (PEF) measurements, rescue 
medication usage, changes in concomitant medication 
and any adverse events. 
At the end of the baseline period, patients were able 
to continue in the study if they exhibited a BCSS total 
score of > 2 for any 7 consecutive days, had not experi- 
enced any exacerbations of COPE), had completed 
diary cards satisfactorily, and had not taken any dis- 
allowed medication. 
At the randomization visit (day I), eligible patients 
were randomized to receive placebo or sibenadet 
(500 I~g) delivered via pMDI (two actuations, three 
times daily). Randomization was performed using 
random permuted blocks to ensure approximately 
equal numbers of patients in each centre received each 
treatment.The sibenadet dose was selected on the 
basis of results from earlier clinical trials (12). Sibenadet 
and placebo inhalers were withdrawn at the end of the 
treatment period and patients were required to 
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continue using only rescue medication (and other 
allowed medications) for a further 4-week follow-up 
period, after which one final clinic visit was made. 
These studies were performed in accordance with 
the principles stated in the Declaration of Helsinki and 
approved by ethics committees at each participating 
centre. All patients gave written informed consent. 
Assessment of symptoms and general 
pulmonary function 
Symptom ratings and pulmonary function were primary 
outcome measures in these studies. Dual primary 
endpoints were selected in order to assess the efficacy 
of both the D 2 and 62 components of sibenadet hrough 
determining changes in BCSS total score and FEV I. 
Changes in COPD symptoms were assessed using the 
BCSS. Each symptom (breathlessness, cough and sputum) 
was evaluated aily by the patient and recorded in a diary 
using a 5-point Likert scale (ranging from 0 to 4, with 
higher values indicating more severe symptoms). The 
three item scores were summed to calculate the BCSS 
total score, resulting in a value between 0 and 12. 
The primary endpoint for assessing symptoms in these 
studies was defined as the difference between the two 
treatment groups in terms of change in mean BCSS total 
score over the baseline period to the mean BCSS total 
score over the final 4 weeks of the treatment period 
(Study I : weeks 9-12; Study 2: weeks 23-26). Changes in 
mean BCSS total score and each of the item scores 
(breathlessness, cough and sputum) from baseline to 
each 2-week period within the treatment period and to 
the follow-up period were also examined. 
The primary endpoint for assessing improvement in 
pulmonary function between the two groups was FEV I 
measured I hour after the final dose of study drug at the 
end of the treatment period (Study I: week 12, Study 2: 
week 26) and expressed as a percentage of predicted 
FEVi.This measure was also assessed at day I (Studies I 
and 2), week4 (Study I) and weeks 6 and 14 (Study2). 
Predicted FEV I was calculated at enrolment using the 
Crapo algorithm (I 3). 
Serial FEV I and PEF assessment 
In a subset of patients (all of whom exhibited > 5% 
reversibility of FEV I in response to inhaled salbutamol 
400 tig), serial FEV I measurements were taken over an 
8-hour period (at 5, 15, 30, 45, 60, 90 and 120 minutes 
and hourly thereafter until 8 hours post-dosing). Serial 
measurements were taken on day l (Studies I and 2), 
weeks 8 and 12 (Study I), and weeks 14 and 26 (Study 2). 
TheAUC0~, mean FEV I at 8 hours and mean maximum 
change from pre-dose were also calculated. These 
measurements were used to investigate the broncho- 
dilator properties of sibenadet- 
Spirometry was used to determine pulmonary 
function at all clinic visits. Patients were instructed not 
to use study or rescue medication 4 hours prior to 
spirometry measurements being taken.After esting for 
15 minutes, slow vital capacity (SVC), FVC, and FEV I 
were measured for at least three separate manoeuvres. 
The greatest values for each parameter were recorded. 
Patients measured PEF each morning and evening, prior 
to taking study medication, and recorded the highest 
value of three manoeuvres in their diary cards. Patients 
were instructed to avoid using rescue medication in the 
4 hours preceding each PEF measurement-The number 
of actuations of rescue medication used each day was 
recorded by patients in their diary cards. 
COPD exacerbations 
COPD exacerbations were defined as worsening 
symptoms of COPD requiring drug therapy in addition 
to study drug, rescue medication and doses of con- 
comitant COPD medications. COPD exacerbations 
since the previous clinic visit were recorded at each 
visit after randomization. Investigators were asked to 
indicate whether each adverse event a patient 
experienced was consistent with the definition of a 
COPD exacerbation. Both adverse events that had 
been flagged by the investigator as an exacerbation and 
adverse events that were described as an 'exacerbation' 
were included in the secondary analysis. 
Health-related quality of life (HRQL) 
HRQL was assessed using the disease-specific St 
George's Respiratory Questionnaire (SGRQ) (14,15) and 
the generic EuroQol-5D (EQ-SD) (16). Questionnaires 
were completed unaided by patients before other study- 
related procedures were performed.This was performed 
at the beginning and end of the treatment period and at 
the end of the follow-up period. In Study 2, an additional 
assessment was made at week 14. 
Patients' and investigators' opinions of 
efficacy 
Patients' opinions of treatment efficacy were recorded at 
all clinic visits after randomization. Opinion was scored 
from 0 to 4, where 0 = highly effective, I = moderately 
effective, 2 = mildly effective, 3 = not effective and 
4 = made condition worse. The investigators recorded 
their opinions at the end of the treatment period only, 
using the same scale. 
Safety 
The safety of study treatment was assessed at each clinic 
visit by examining the incidence of adverse events. In 
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addition, clinically significant changes in laboratory and 
other safety variables (ECG, pulse and blood pressure, 
physical signs) were assessed at the start and end of the 
study. 
Statistical analyses 
An intention to treat population (I'I-F) was defined as all 
randomized patients receiving at least one dose of study 
medication with useable post-randomization efficacy 
data, and was used to summarize all efficacy data 
according to the treatment the patient was randomized 
to receive. In addition, exploratory sensitivity analyses 
were performed using this population to assess the 
impact of data missing due to patient withdrawal from 
the study. A safety population was defined as all 
randomized patients receiving at least one dose of study 
medication and was used to summarize all safety data 
according to the treatment the patient received. 
The primary hypotheses were tested using analysis of 
covariance with treatment and country as fixed factors. 
The BCSS primary endpoint included the mean BCSS 
total score over the baseline period as a covariate, and 
the FEV t primary endpoint included the value for FEV t 
recorded immediately prior to the final dose of study 
medication and expressed as a percentage of the 
predicted FEVj, as a covariate. These tests were two- 
sided and both performed at the 5% significance level. All 
assumptions implicit in the ANCOVA methodology were 
checked and potential interactions were investigated. 
Supportive and exploratory analyses were conducted 
on the secondary efficacy variables using analysis of 
covariance including treatment and country as fixed 
factors and a baseline value as a covariate for continuous 
variables, and using the chi-square test for categorical 
variables. No correction was made to the significance 
level given both the non-confirmatory purpose of the 
analyses, and that the study was not prospectively 
powered to detect differences in these secondary 
variables. 
The sample size calculation was based on the mean 
differences from baseline and associated variability 
shown in the Phase lib study (12). A total of 371 patients 
in each treatment group were required to show a 
difference of at least 0.34 between treatment groups in 
the change from baseline in mean BCSS total score, 
assuming a pooled standard deviation of 1.425; 217 
patients in each treatment group were required to show 
a difference of at least 5% in FEV I expressed as a 
percentage of predicted FEV t I hour after the final dose 
of study drug, assuming a pooled standard deviation of 
16.Therefore, it was aimed that a minimum of 950 and 
1060 patients be randomized into Studies l and2 
respectively to ensure that at least 742 patients would 
complete each study. 
Patients enrolled 
Study 1: n=-I 147 Study  2 :n=1476 
Patients randomized 











Study 1: n=480 
Study 2:n=-500 
FIGURE I. Flow chart of patient disposition. 
RESULTS 
Patient demographics 
Patient disposition for Studies I and 2 is summarized in 
Figure I.The safety population comprised 1072 and 1203 
patients in Studies I and 2 respectively. The IT'I" population 
comprised fewer patients (1050 and II 69 respectively) as 
patients from two centres in each study were excluded as 
their efficacy data was deemed unreliable.The decision to 
exclude these patients from the ITT population was taken 
prior to unblinding the study. 12% and 17% of patients in 
the safety population withdrew from Studies l and2 
respectively, the primary reasons being adverse events, 
deterioration of patient condition, withdrawal of consent 
or a protocol deviation. In each of the studies, the 
proportion of patients withdrawing in each treatment 
group was similar with no obvious differences in the 
reasons for withdrawal. 
The baseline characteristics of patients in the I-I-r 
populations are summarized in Table I. Any differences 
noted between treatment groups at baseline were not 
considered clinically relevant. 
Compliance with study medication as recorded by the 
patients on their diary cards was high. The mean 
percentage compliance with study medication was 97% 
across all treatment groups in both studies. 
Symptom ratings 
The Least Squares (LS) mean differences from baseline 
to the final 4 weeks of treatment are outlined in Table 2, 
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a decrease in LS mean signifying improvement in 
symptoms. Although the results indicate a greater 
decrease in BCSS total score in the sibenadet group than 
in the placebo group, these differences were neither 
statistically significant nor considered to be of clinical 
significance ( 12,13). 
Sensitivity analyses were performed using the mean of 
the BCSS total scores recorded in 3 days prior to with- 
drawal from the study to represent the daily score to the 
end of the scheduled treatment period. Although these 
data yielded larger LS mean estimates for the difference 
between the two treatment groups, they did not represent 
differences judged to be of clinical importance. 
At the start of the treatment period in both studies, 
there was an immediate reduction in BCSS total score in 
the sibenadet group, followed by a gradual increase in 
symptom scores, indicating an initial symptom improve- 
ment and subsequent deterioration (Figure2a, b). In 
Study I, the LS mean difference in BCSS total score 
between the two groups (for the whole of the treatment 
period) was -0-39 with a corresponding 95% confidence 
interval of (-0.55, -0-22); P < 0.00 I. In Study 2, the LS 
mean difference in BCSS total score (for the whole of 
the treatment period) between the two treatment 
groups was -0.22 (95% CI -0-37, -0.07); P=0"005. 
Neither the sibenadet group nor the placebo group 
returned to the mean BCSS total score recorded during 
the baseline period. 
There were initial decreases from baseline for each of 
the mean BCSS item symptom scores (breathlessness, 
cough and sputum) at the start of treatment in the 
sibenadet groups. A gradual increase in the symptom 
scores was, however, subsequently seen. 
Pulmonary function I hour post-dose 
In Study I, the LS mean FEV I expressed as a % of 
predicted FEV I I hour after taking the final dose of study 
drug at the end of the scheduled treatment period 
(week 12) for placebo was 40.20 (SE + 0.5 I, n=415), and 
for sibenadet was 44.59 (+ 0"51, n=430). The least 
squares (LS) mean difference between sibenadet and 
placebo groups (n=845) was 4.39% (SE + 0.59) predicted 
FEV= (95% CI 3.2, 5.6). In Study 2, the LS mean FEV I at 
week 26 for placebo was 41 "83 (SE + 0"52, n=419), and 
for sibenadet was 47.31 (SE + 0-5 I, n=423).The LS mean 
difference between the sibenadet and placebo groups 
(n=842) was 5.47% (SE + 0.66) predicted FEV I (95% CI 
4.2, 6.8). Both results were highly statistically significant 
(P < 0.00 t). 
Including FEV I measurements made closest to the end 
of the treatment period for patients who withdrew (i.e., 
last observation carried forward) demonstrated similar 
results. 
Serial FEV t measurements 
Serial measurements of FEV I were obtained from a subset 
of patients (Study I: n= 130; Study 2: n= 152). FEV I continued 
to increase for up to 2 hours post-dose in the sibenadet 
group. In both studies, an increase from pre-dose FEV t was 
noted 5 minutes after study drug in patients randomized to 
sibenadet. The maximum increase (LS mean maximum 
difference from placebo) was between I and 2 hours after 
study drug. At weeks8 and 12 (Study I) and weeks 14 
and 26 (Study 2) there were smaller increases in FEV I and 
the duration of effect is seen to diminish (Figure 3). 
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FIGURE 2. Summary of change from baseline in mean BCSS over the treatment period, a) Intention to treat (17-I) population, all 
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FIGURE 3. Serial FEV I over 8 hour (data from Study 2, excluding post-rescue medication measurements). 
TheAUC0_ 8 for the change from pre-dose in FEV I was 
greater for the sibenadet group compared with the 
placebo group in both studies. The actual value of 
AUC0~ in the sibenadet group was greater for the serial 
FEV I measurements taken on day l than for the 
measurements taken at weeks8 and 12 (Study I) or 
weeks 14 and 26 (Study2) (Table3). All differences in 
AUC0~ between the sibenadet and placebo groups were 
statistically significant. 
Other  measures  o f  e f f i cacy  
There was an immediate increase in the morning and 
evening PEF at the start of the treatment period in the 
sibenadet group. This increase appeared to be 
maintained for the duration of the treatment period. In 
the placebo group, there was a gradual increase in both 
morning and evening PEF.These increases were smaller 
than the increases observed for the sibenadet group. 
The LS mean difference between the treatment groups in 
both morning and evening PEF (from baseline to last 
4 weeks of study period) were; Study I a.m. 12" I (95% CI 
7.4, 16.8), p.m. 13"0 (95% CI 8" I, 17-8); Study 2 a.m. 12-4 
(95% CI 7.0, 17.7), p.m. 13.5 (95% CI 8.3, 18.8) (P < 0.00 I 
in both studies). The clinical relevance of these 
differences is unclear. 
In the sibenadet group there appeared to be an 
increase in SVC, FEV I and FVC from the baseline period 
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(Visit 2) to subsequent visits over the treatment period. 
The magnitude of these increases diminished as the 
treatment period progressed. In the placebo group, 
there was little change from baseline to each of the 
subsequent visits during the treatment period. 
However, there was an increase in these pulmonary 
function variables from the baseline to the follow-up 
period. 
There was a gradual increase in the mean number of 
actuations of rescue medication recorded by patients in 
both treatment groups over the baseline period. There 
was an immediate decrease in the number of actuations 
of rescue medication taken at the start of the treatment 
period, in both treatment groups. The decreases 
observed appeared to be maintained for the duration of 
the treatment period. The LS mean difference in the 
change from baseline to the final 4weeks of the 
treatment period was: Study I : - I "51 actuations per day 
(95% CI -I.89, -I.15), Study 2: - I .  I actuations per day 
(95% CI - I .47,-0.75).  The differences between the 
placebo and sibenadet groups were statistically significant 
at all time intervals examined (P < 0.001). At the start of 
the follow-up period there was an immediate increase in 
the daily number of actuations of rescue medication 
taken in each treatment group, which in Study 2 was 
more marked in the sibenadet group. 
Health-related quality of life 
In both studies, SGRQ total and domain scores of 
patients receiving sibenadet showed reduction from 
baseline to the end of the treatment period, although 
reduced scores were also seen in the placebo groups. In 
Study I, large changes were observed in both the 
sibenadet and placebo groups for the symptom domain 
(LS mean difference of-8.2 [SE + 1.0] in the sibenadet 
group and -5.9 [SE + I. I] in the placebo group). For the 
SGRQ total score and the remaining domain scores 
(activity and impacts), the differences between the two 
treatment groups in their respective changes from 
baseline scores showed a trend towards superiority of 
sibenadet, but no statistically significant differences were 
seen. For both treatment groups in Study2 the 
improvement in symptom domain from baseline to 
week 14 was statistically significant (LS mean changes of 
-4. I [SE + 0.4] and -6.6 [SE + 0.9] for the placebo and 
sibenadet groups, respectively). However, this difference 
was not maintained by week26 (-5"0 and -5.2 
respectively) (Figure 4). 
The EQ-5D data obtained from both studies failed to 
demonstrate any differences in weighted health index 
between the treatment groups. An improvement in 
patients' evaluation of their own health was seen in 
patients receiving sibenadet in Study I. 
Patient and investigator opinion of 
efficacy 
In both studies, sibenadet reatment was more frequently 
considered to be highly or moderately effective than 
placebo. At the end of Study I, 23% of investigators and 
34% of patients rated placebo as highly or moderately 
effective. In contrast 52% of investigators and 62% of 
patients rated sibenadet as highly or moderately 
effective. At the end of Study 2, 26% of investigators and 
39% of patients rated placebo as highly or moderately 
effective.Again, a higher proportion of investigators and 
patients rated sibenadet as highly or moderately effective 
(52% and 59% respectively). 
Exacerbations 
The proportion of patients experiencing at least one 
exacerbation was similar in both study groups (Study I: 
17.9%114.7% placebo and sibenadet groups respectively; 
Study2: 25"8%/23"5% placebo and sibenadet groups 
respectively). There was also no difference in the time to 
the first exacerbation between the two treatment 
groups. 
Adverse events 
The most frequently reported adverse events starting in 
the treatment period are summarized in Table 4. No 
differences were seen in the incidence of serious adverse 
events between the placebo and sibenadet groups of 
either study during the treatment and follow-up period. 
A similar proportion of patients in placebo and sibenadet 
groups discontinued study drug due to adverse events 
(Study I: 7% and 5% respectively; Study 2: 8% and 10% 
respectively). Respiratory events were the most frequent 
type of event resulting in discontinuation, namely 
deterioration of chronic obstructive airways disease and 
aggravated dyspnoea. 
In both studies, the majority of laboratory abnormalities 
were not considered clinically significant and no 
differences between the sibenadet and placebo groups 
were evident.Vital signs and ECG abnormalities occurred 
as isolated incidents. In Study 2 there was an excess of 
ECG abnormalities recorded as adverse events in the 
sibenadet group but the nature of these abnormalities 
was diverse and fell into no distinguishable pattern.There 
were no clinically relevant rends evident from vital signs 
data or from the changes in numbers of aggravated 
abnormalities found on physical examination. 
In Study I, three deaths were reported during the 
treatment period (two in the sibenadet, one in the placebo 
group) and four deaths during follow-up (two in both 
treatment groups).Two deaths were considered probably 
or possibly due to study drug: one placebo patient with 
exacerbation of chronic obstructive airways disease and 
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FIGURE 4. Least squares mean changes from baseline to the end of the treatment period in SGRQ scores (bars indicate standard 
error; Intention to treat (ITI-) population, data from Study 2). 
one sibenadet patient with acute hepatitis. In Study 2 there 
were six deaths during the treatment period (two in the 
sibenadet group, four in the placebo group) and 15 deaths 
during follow-up (10in the sibenadet group, five in the 
placebo group).Two deaths were considered probably or 
possibly due to study drug: one placebo patient (fatal 
ventricular tachycardia and fibrillation) and one sibenadet 
patient (myocardial infarction). 
DISCUSSION 
In both studies reported, sibenadet therapy (pMDI 
500 Ilg three times daily) was initially more effective 
than placebo in reducing COPD symptoms, as 
determined by a reduction in mean daily BCSS total 
score.This initial improvement was consistent with the 
promising efficacy seen in the initial clinical studies over 
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a similar timeframe (12). However, this initial effect 
diminished over the course of the treatment period 
and by the end of the study differences were of neither 
statistical nor clinical significance. Although sympto- 
matic improvement in the sibenadet group was more 
marked at the beginning of the study, the placebo group 
also demonstrated improved symptomatology over the 
course of the study, with both treatment groups 
exhibiting lower mean BCSS total scores at the end of 
the study period than baseline values. 
While it may be noted that baseline demographics 
indicate that the study represented a relatively severe 
COPD population, mean BCSS total scores at baseline 
were relatively low. As patient severity is determined 
according to pulmonary function measurements 
(largely FEVI), it would appear that airflow limitation is 
not directly reflective of symptom severity. This 
observation highlights the need to assess patient 
symptoms and supports the use of a dual endpoint to 
determine changes in COPD symptoms as well as 
pulmonary function. A patient-reported outcome 
measure, such as the BCSS, is a highly appropriate 
approach to detecting changes in patient symptoms. 
Use of this tool in well-designed and adequately 
powered studies has enabled clear conclusions 
regarding sibenadet efficacy to be drawn. 
FEV I measurements clearly demonstrated the 
significant bronchodilatory effects of sibenadet, with 
serial FEV I assessments demonstrating an immediate 
improvement.The duration and magnitude of these 
effects was not, however, maintained throughout the 
study course, as reflected by decreased pulmonary 
function over time.The reduced bronchodilator effect 
of sibenadet seen over the course of the study can 
most likely be attributed to tachyphylaxis, a recognized 
potential response to regular ~2-agonist use. The 
mechanisms for this effect are unclear, but could be 
brought about by down-regulation of ~-receptors, 
changes in regulatory mechanisms, or the high potency 
of sibenadet at the 132-receptors (9). It remains to be 
determined whether this phenomenon was active in all 
patients or in just a subset of patients with a particular 
genetic background. 
The fact that initial improvements in symptomato- 
Iogy tailed off over time could be indicative of 
tolerance to sibenadet- One explanation may be that 
the early symptomatic benefit was ~2- rather than 
D2-driven and symptomatic benefits therefore 
diminished in response to tachyphylaxis to the 
132-agonist activity. It is also possible that the ~2-effect, 
through reducing the perception of breathlessness, 
resulted in the perception of general symptom 
improvement. Support for a direct effect of D 2 agonism 
on the cough component has, however, been 
demonstrated in an early study of sibenadet, which 
established that Dzdopamine receptor agonism 
effectively inhibits aerosol-induced cough (9,17). 
Alternatively, it is possible that the tachyphylaxis of 
~2-agonist effects diminishes the total efficacy of the 
dual D2/132 mechanism of action, thereby effectively 
masking the D2component. It is likely that the 
improvement noted for the Breathlessness core in the 
sibenadet group at the end of the treatment period was 
due to the bronchodilator activity of sibenadet- This is 
supported by the observation that this is most marked 
in the shorter-term study, whereas in the 6-month 
study it is possible that tachyphylaxis has diminished 
this result by the end of the treatment period. 
It is important o note that tolerance to the positive 
effects of sibenadet on pulmonary function and COPD 
symptoms was not associated with increased exacerba- 
tions, or increased use of rescue therapy.This indicates 
that this phenomenon was not associated with an 
adverse clinical outcome. 
Despite the apparent lack of symptomatic benefits in 
these studies, these data demonstrate the need for a 
tool such as the BCSS in order to assess therapeutic 
effects in terms of symptom improvement. It is 
apparent that, although peak flow and rescue medi- 
cation use remained stable throughout the study, 
symptomatic benefit deteriorated illustrating that sole 
reliance on pulmonary function provides an incomplete 
picture of patient response to a therapeutic 
intervention. This emphasizes the need for routine 
measurements of other endpoints in COPD clinical 
trials in addition to pulmonary function. 
Large changes in SGRQ were demonstrated, 
particularly for the symptoms domain, but a 
considerable placebo effect was also seen. Whilst it is 
difficult to interpret he clinical meaning of these data, 
it may be that the improvement in SGRQ in placebo 
patients is simply a result of the patients' involvement 
in the clinical study. COPD patients classically 
represent an isolated and often depressed population 
who may benefit greatly from the attention and regular 
contact inherent in the clinical trial environment-This 
theory is perhaps supported by the fact that, while 
over half the patients considered sibenadet to be 
either highly or moderately effective, approximately 
one third also perceived this level of efficacy with the 
placebo. 
Sibenadet had an acceptable safety and tolerability 
profile with few differences in incidence between the 
treatment groups, with the exception of respiratory 
infection, taste of treatment and tremor (a known 
1~2-adrenoceptor agonist effect), which occurred more 
frequently in the sibenadet group.While D 2 agonists are 
known to induce nausea, vomiting, dizziness and 
somnolence, the frequencies of these events were low 
and were similar in both treatment groups, confirming 
the lack of centrally mediated D 2 effects with sibenadet 
use. 
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In conclusion, despite a well-founded theoretical 
rationale for sibenadet efficacy, supported by promising 
preclinical and early clinical data, the clinical 
development programme has enabled clear conclusions 
to be drawn regarding the long-term clinical benefit of 
sibenadet therapy. Initial symptomatic benefits were 
not sustained throughout the duration of the studies 
and these studies therefore demonstrated no evidence 
of long-term, clinically significant D2agonist effect. 
Sibenadet therefore does not appear to offer any 
additional benefit over existing bronchodilator therapy 
for COPD, and clinical development of this agent has 
now been discontinued. 
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